{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Weisinger J"],"pubmed_abstract":["<h4>Background</h4>Despite improvement in acute care of immune-mediated thrombotic thrombocytopenic purpura (iTTP), numerous studies showed that patients with iTTP have inferior mental health and health-related quality of life (HRQoL). Caplacizumab led to shorter hospitalization, less plasma exchange, and improved survival in iTTP and might influence long-term HRQoL.<h4>Objectives</h4>We aimed to address the impact of iTTP on HRQoL, posttraumatic stress disease, depression, and anxiety, as well as the possible role of caplacizumab on improving these features.<h4>Methods</h4>We conducted a survey among patients with iTTP enrolled in the French thrombotic microangiopathy registry: patients completed the Short Form (SF)-36 HRQoL, the Hospital Anxiety and Depression Scale screening for anxiety"],"journal":["Research and practice in thrombosis and haemostasis"],"pagination":["103297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804100"],"repository":["biostudies-literature"],"pubmed_title":["Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab era."],"pmcid":["PMC12804100"],"pubmed_authors":["Azoulay E","Augusto JF","Choukroun G","Joly B","Jaccard A","Moranne O","Poullin P","Weisinger J","Veyradier A","Papo T","Presne C","Bouzid R","Fadlallah J","Cartery C","Lievre L","Coppo P","Tites C","Benhamou Y","Baba A","Gilardin L"],"additional_accession":[]},"is_claimable":false,"name":"Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab era.","description":"<h4>Background</h4>Despite improvement in acute care of immune-mediated thrombotic thrombocytopenic purpura (iTTP), numerous studies showed that patients with iTTP have inferior mental health and health-related quality of life (HRQoL). Caplacizumab led to shorter hospitalization, less plasma exchange, and improved survival in iTTP and might influence long-term HRQoL.<h4>Objectives</h4>We aimed to address the impact of iTTP on HRQoL, posttraumatic stress disease, depression, and anxiety, as well as the possible role of caplacizumab on improving these features.<h4>Methods</h4>We conducted a survey among patients with iTTP enrolled in the French thrombotic microangiopathy registry: patients completed the Short Form (SF)-36 HRQoL, the Hospital Anxiety and Depression Scale screening for anxiety","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-10T05:15:11.792Z","creation":"2026-06-10T03:07:29.693Z"},"accession":"S-EPMC12804100","cross_references":{"pubmed":["41552747"],"doi":["10.1016/j.rpth.2025.103297"]}}